PCRopsis™ Reagent RVD + PCRopsis™ RVD Enhancer offers a direct PCR solution for specimens in most non-inactivating transport mediums.

PCRopsis™ Reagent RVD alone has been repeatedly shown to facilitate extraction-free amplification of viral, bacterial, and mammalian specimens in universal viral transport (UVT) mediums, like BD™ Universal Viral Transport system. This is one of the most common specimen transport mediums in the U.S., although many other transport mediums are used in the U.S. and abroad.

Entopsis developed PCRopsis™ RVD Enhancer to expand the compatibility of PCRopsis™ Reagent RVD to process specimens in diverse transport mediums. PCRopsis™ Reagent RVD, when used in

PCRopsis™ Reagent RVD was recently shown to mediate direct PCR amplification from viral and bacterial targets using low volumes of reagent and sample, thus drastically lowering costs and increasing testing accessibility.

Reagent RVD is a flexible direct PCR product for various research and clinical applications. The PCR testing industry is particularly price-conscious, with thin profit margins. As such, laboratories seek affordable and accurate solutions to offer clients the best services.

Recent miniaturization studies confirm Reagent RVD facilitates extraction-free RT-PCR and qPCR for less than $1.70 per reaction. Typically, RNA and DNA extraction kits cost $4.00 ~ $7.00 per extraction (2~4

Have you ever read about cool, new medical products / tests, only to later realize it won’t be available for years into the future (if ever)?

Entopsis is effectively a R&D company that creates novel, impactful technologies for the bio-medical space. They are best known for OpsisDx (single platform to diagnose diseases early through urine) and PCRopsis (clinical tools that make diagnostic tests more efficient). This team of hard-core scientists and engineers usually rather license technologies, than sell directly to consumers.

This is where the Global Health Institute (GHI) comes in. GHI’s mission is to de-risk new clinical technologies by

Reagent RVD has proven capable of amplifying SARS-CoV-2 gene targets directly from universal viral transport (UVT) medium without the need for viral RNA extraction. However, diagnostic reference laboratories also want to use this approach for the amplification of bacterial gene targets.

The PCRopsis research team has extended their validation efforts in this direction. It’s been confirmed that Reagent RVD is capable of mediating extraction-free qPCR of specimens containing gram positive and negative bacteria.

To date, Reagent RVD facilitates extraction-free amplification of viral, bacterial and human gene targets directly from UVT.

This opens the door to new applications with Reagent

The U.S. National Academy of Medicine’s Healthy Longevity Global Grand Challenge has awarded a grant to develop Entopsis’ OpsisDx(TM) platform for detecting Parkinson’s disease using skin swabs or urine. This effort is driven by Entopsis’ scientific and clinical collaborators at Singapore’s Temasek Life Sciences Laboratory (TLL) and National Neuroscience Institute (NNI).

Read more about it here:

https://www.einnews.com/pr_news/529273833/national-academy-of-medicine-selects-opsisdx-for-co-development-of-a-urine-based-diagnostic-for-parkinson-s-disease

Non-invasive OpsisDx Diagnostic Test Awarded US Academy Research Grant

Our team’s passion is to innovate and create powerful, unheard-of solutions to the world’s problems. We pride ourselves on our creativity and desire to make a meaningful difference, both socially and scientifically.

However, we can only achieve our global goals with the right partners that share our mission. Today’s press release (see below) highlights one such partner, Madison Core Labs.

Link to Press Release

Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients

August 13, 2020 09:05 AM Eastern Daylight Time

HUNTSVILLE, Ala.–(BUSINESS WIRE)–Read more

Genetics Institute of America (GIA) received IRB approval to expand its Prostate Cancer Study (GH215) utilizing OpsisDx to include: Breast, Ovarian and Lung Cancers. OpsisDx will be used to develop accurate, non-invasive tests for the early detection of these 3 additional cancers.

GIA, empowered by OpsisDx, will be able to screen people for prostate, breast, ovarian, and / or lung cancers once these 4 studies are completed. These tests are expected to detect tumors earlier than liquid biopsies and thereby outperform GRAIL (valued at over $4 billion).

The Entopsis team will continue to support GIA’s efforts of bring impactful tools

Is viral RNA extraction necessary for amplifying genes from coronaviruses, like SARS-CoV-2?

NOT ANY MORE!

PCRopsis Reagent RVD allows you to perform direct RT-qPCR from nasopharyngeal / oropharyngeal samples transported in BD Universal Viral Transport media or Copan ESwab.

Simple Protocol:

  1. Mix sample 1:1 with Reagent RVD
  2. Heat to 95C for 10 minutes
  3. DONE… use ~5 uL into your RT-qPCR mix (can use 5 uL into a total 20 uL reaction)

Key Features:

  • Reagent RVD is an alternative to RNA extraction
  • Offers comparable RT-qPCR results to RNA extraction procedures for many applications in 10 MINUTES
  • Cost a fraction of traditional RNA extraction procedures, with fewer steps
  • Compatible with leading

“The U.S. Food and Drug Administration (FDA) reminds laboratory staff to use transport media (the liquid that maintains a specimen sample while it is transported to a laboratory) that are compatible with the SARS-CoV-2 testing platforms and the processes used in their laboratory to process samples collected from people who are being tested for SARS-CoV-2. There is a risk of exposure to harmful cyanide gas, a by-product of a reaction between guanidine thiocyanate or similar chemicals and bleach (sodium hypochlorite), when certain transport media are used with an incompatible testing platform or laboratory process. Guanidine thiocyanate may be referred to

‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

In modern times, cardiovascular disease (CVD) has become just as worrisome as epidemics in the early stages of medicine. Currently, CVD accounts for around 50% of deaths in richer countries, making it an important area for research, therapeutics and diagnostics. 

Known cardiovascular risk factors include lipid disorders, high blood pressure, smoking, obesity, diabetes and sedentariness (1). Although these risk factors are broad and encompass many areas, the influence of the microbiome, complex stress responses and psychiatric disorders also